Eurocell Plc
Total Valuation
USDAs of June 30, 2026, EUROCELL PLC carries a market capitalization of 129.38M, placing it among publicly traded companies globally. Its enterprise value stands at 253.51M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 129.38M |
| Enterprise Value | 253.51M |
Important Dates
EUROCELL PLC's next confirmed earnings release is scheduled for March 25, 2027.
| Earnings Date | 3/25/2027 |
Share Statistics
As of June 30, 2026, EUROCELL PLC has 99.12M shares outstanding.
| Shares Outstanding | 99.12M |
Valuation Ratios
These figures are as of June 30, 2026.
| PB Ratio | 0.99 |
| P/TBV Ratio | 1.70 |
Financial Position
As of June 30, 2026, EUROCELL PLC maintains a current ratio of 1.42, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.42 |
| Quick Ratio | 0.08 |
| Debt / Equity | 102.85 |
Financial Efficiency
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 2,301.00 |
Stock Price Statistics
As of the close on September 25, 2026, EUROCELL PLC's stock has declined approximately 11.33% over the past 52 weeks.
| 52-Week Price Change | -11.33% |
Balance Sheet
USDAs of June 30, 2026, EUROCELL PLC holds 10.08M in cash and equivalents against 134.21M in total debt, resulting in a net debt position of 37.13M. Total book value stands at 130.49M, with working capital of 51.99M providing operational flexibility.
| Cash & Cash Equivalents | 10.08M |
| Total Debt | 134.21M |
| Net Debt | 37.13M |
| Equity (Book Value) | 130.49M |
| Book Value Per Share | 1.32 |
| Working Capital | 51.99M |